COVID-19 vaccines: Immune correlates and clinical outcomes
Severe disease due to COVID-19 has declined dramatically as a result of widespread vaccination and natural immunity in the population. With the emergence of SARS-CoV-2 variants that largely escape vaccine-elicited neutralizing antibody responses, the efficacy of the original vaccines has waned and h...
Gespeichert in:
| Veröffentlicht in: | Human vaccines & immunotherapeutics 2024-12, Vol.20 (1), p.2324549 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 2324549 |
| container_title | Human vaccines & immunotherapeutics |
| container_volume | 20 |
| creator | Mahrokhian, Shant H. Tostanoski, Lisa H. Vidal, Samuel J. Barouch, Dan H. |
| description | Severe disease due to COVID-19 has declined dramatically as a result of widespread vaccination and natural immunity in the population. With the emergence of SARS-CoV-2 variants that largely escape vaccine-elicited neutralizing antibody responses, the efficacy of the original vaccines has waned and has required vaccine updating and boosting. Nevertheless, hospitalizations and deaths due to COVID-19 have remained low. In this review, we summarize current knowledge of immune responses that contribute to population immunity and the mechanisms how vaccines attenuate COVID-19 disease severity. |
| doi_str_mv | 10.1080/21645515.2024.2324549 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_38517241</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d5cddb4db5dc402cb1d85766789d8d24</doaj_id><sourcerecordid>2974004172</sourcerecordid><originalsourceid>FETCH-LOGICAL-c535t-83db1805d776025720a37ea80ad2b0bf1cc774865ebd026feb1a0212daa121b33</originalsourceid><addsrcrecordid>eNp9kUtv1DAURi0EolXpTwBlySaD7fiVbgANr5EqddNW7KzrR4orxy52UtR_T6YzHdEN3ti6Pvdcyx9CbwleEazwB0oE45zwFcWUrWhHGWf9C3S8rbecs58vD2fCj9Bprbd4WXKhhXiNjjrFiaSMHKOz9cX15ktL-uYerA3J17NmM45z8o3NpfgIk68NJNfYGFKwEJs8TzaPvr5BrwaI1Z_u9xN09e3r5fpHe37xfbP-fN5a3vGpVZ0zRGHupBSYckkxdNKDwuCowWYg1krJlODeOEzF4A0BTAl1AIQS03UnaLPzugy3-q6EEcqDzhD0YyGXGw1lCjZ67bh1zjBnuLMMU2uIU1wKIVXvlKNscX3cue5mM3pnfZoKxGfS5zcp_NI3-V4T3AsqiFoM7_eGkn_Pvk56DNX6GCH5PFdNe8kwZsv3LijfobbkWosfDnMI1tsc9VOOepuj3ue49L3795GHrqfUFuDTDghpyGWEP7lEpyd4iLkMBZINVXf_n_EXg_mrNA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2974004172</pqid></control><display><type>article</type><title>COVID-19 vaccines: Immune correlates and clinical outcomes</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Access via Taylor & Francis (Open Access Collection)</source><source>Alma/SFX Local Collection</source><creator>Mahrokhian, Shant H. ; Tostanoski, Lisa H. ; Vidal, Samuel J. ; Barouch, Dan H.</creator><creatorcontrib>Mahrokhian, Shant H. ; Tostanoski, Lisa H. ; Vidal, Samuel J. ; Barouch, Dan H.</creatorcontrib><description>Severe disease due to COVID-19 has declined dramatically as a result of widespread vaccination and natural immunity in the population. With the emergence of SARS-CoV-2 variants that largely escape vaccine-elicited neutralizing antibody responses, the efficacy of the original vaccines has waned and has required vaccine updating and boosting. Nevertheless, hospitalizations and deaths due to COVID-19 have remained low. In this review, we summarize current knowledge of immune responses that contribute to population immunity and the mechanisms how vaccines attenuate COVID-19 disease severity.</description><identifier>ISSN: 2164-5515</identifier><identifier>ISSN: 2164-554X</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2024.2324549</identifier><identifier>PMID: 38517241</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Antibodies, Neutralizing ; Antibodies, Viral ; Coronavirus ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 Vaccines ; Humans ; immune correlates ; mucosal immunity ; Review ; SARS-CoV-2 ; SARS-CoV-2 variants ; T-cells ; Vaccination ; vaccines</subject><ispartof>Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2324549</ispartof><rights>2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024</rights><rights>2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c535t-83db1805d776025720a37ea80ad2b0bf1cc774865ebd026feb1a0212daa121b33</citedby><cites>FETCH-LOGICAL-c535t-83db1805d776025720a37ea80ad2b0bf1cc774865ebd026feb1a0212daa121b33</cites><orcidid>0000-0001-5127-4659 ; 0000-0003-4094-8739</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2324549$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/21645515.2024.2324549$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,864,885,2102,27502,27924,27925,59143,59144</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38517241$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mahrokhian, Shant H.</creatorcontrib><creatorcontrib>Tostanoski, Lisa H.</creatorcontrib><creatorcontrib>Vidal, Samuel J.</creatorcontrib><creatorcontrib>Barouch, Dan H.</creatorcontrib><title>COVID-19 vaccines: Immune correlates and clinical outcomes</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>Severe disease due to COVID-19 has declined dramatically as a result of widespread vaccination and natural immunity in the population. With the emergence of SARS-CoV-2 variants that largely escape vaccine-elicited neutralizing antibody responses, the efficacy of the original vaccines has waned and has required vaccine updating and boosting. Nevertheless, hospitalizations and deaths due to COVID-19 have remained low. In this review, we summarize current knowledge of immune responses that contribute to population immunity and the mechanisms how vaccines attenuate COVID-19 disease severity.</description><subject>Antibodies, Neutralizing</subject><subject>Antibodies, Viral</subject><subject>Coronavirus</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>Humans</subject><subject>immune correlates</subject><subject>mucosal immunity</subject><subject>Review</subject><subject>SARS-CoV-2</subject><subject>SARS-CoV-2 variants</subject><subject>T-cells</subject><subject>Vaccination</subject><subject>vaccines</subject><issn>2164-5515</issn><issn>2164-554X</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kUtv1DAURi0EolXpTwBlySaD7fiVbgANr5EqddNW7KzrR4orxy52UtR_T6YzHdEN3ti6Pvdcyx9CbwleEazwB0oE45zwFcWUrWhHGWf9C3S8rbecs58vD2fCj9Bprbd4WXKhhXiNjjrFiaSMHKOz9cX15ktL-uYerA3J17NmM45z8o3NpfgIk68NJNfYGFKwEJs8TzaPvr5BrwaI1Z_u9xN09e3r5fpHe37xfbP-fN5a3vGpVZ0zRGHupBSYckkxdNKDwuCowWYg1krJlODeOEzF4A0BTAl1AIQS03UnaLPzugy3-q6EEcqDzhD0YyGXGw1lCjZ67bh1zjBnuLMMU2uIU1wKIVXvlKNscX3cue5mM3pnfZoKxGfS5zcp_NI3-V4T3AsqiFoM7_eGkn_Pvk56DNX6GCH5PFdNe8kwZsv3LijfobbkWosfDnMI1tsc9VOOepuj3ue49L3795GHrqfUFuDTDghpyGWEP7lEpyd4iLkMBZINVXf_n_EXg_mrNA</recordid><startdate>20241231</startdate><enddate>20241231</enddate><creator>Mahrokhian, Shant H.</creator><creator>Tostanoski, Lisa H.</creator><creator>Vidal, Samuel J.</creator><creator>Barouch, Dan H.</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5127-4659</orcidid><orcidid>https://orcid.org/0000-0003-4094-8739</orcidid></search><sort><creationdate>20241231</creationdate><title>COVID-19 vaccines: Immune correlates and clinical outcomes</title><author>Mahrokhian, Shant H. ; Tostanoski, Lisa H. ; Vidal, Samuel J. ; Barouch, Dan H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c535t-83db1805d776025720a37ea80ad2b0bf1cc774865ebd026feb1a0212daa121b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibodies, Neutralizing</topic><topic>Antibodies, Viral</topic><topic>Coronavirus</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>Humans</topic><topic>immune correlates</topic><topic>mucosal immunity</topic><topic>Review</topic><topic>SARS-CoV-2</topic><topic>SARS-CoV-2 variants</topic><topic>T-cells</topic><topic>Vaccination</topic><topic>vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mahrokhian, Shant H.</creatorcontrib><creatorcontrib>Tostanoski, Lisa H.</creatorcontrib><creatorcontrib>Vidal, Samuel J.</creatorcontrib><creatorcontrib>Barouch, Dan H.</creatorcontrib><collection>Access via Taylor & Francis (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mahrokhian, Shant H.</au><au>Tostanoski, Lisa H.</au><au>Vidal, Samuel J.</au><au>Barouch, Dan H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19 vaccines: Immune correlates and clinical outcomes</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2024-12-31</date><risdate>2024</risdate><volume>20</volume><issue>1</issue><spage>2324549</spage><pages>2324549-</pages><issn>2164-5515</issn><issn>2164-554X</issn><eissn>2164-554X</eissn><abstract>Severe disease due to COVID-19 has declined dramatically as a result of widespread vaccination and natural immunity in the population. With the emergence of SARS-CoV-2 variants that largely escape vaccine-elicited neutralizing antibody responses, the efficacy of the original vaccines has waned and has required vaccine updating and boosting. Nevertheless, hospitalizations and deaths due to COVID-19 have remained low. In this review, we summarize current knowledge of immune responses that contribute to population immunity and the mechanisms how vaccines attenuate COVID-19 disease severity.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>38517241</pmid><doi>10.1080/21645515.2024.2324549</doi><orcidid>https://orcid.org/0000-0001-5127-4659</orcidid><orcidid>https://orcid.org/0000-0003-4094-8739</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2164-5515 |
| ispartof | Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2324549 |
| issn | 2164-5515 2164-554X 2164-554X |
| language | eng |
| recordid | cdi_pubmed_primary_38517241 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Access via Taylor & Francis (Open Access Collection); Alma/SFX Local Collection |
| subjects | Antibodies, Neutralizing Antibodies, Viral Coronavirus COVID-19 COVID-19 - prevention & control COVID-19 Vaccines Humans immune correlates mucosal immunity Review SARS-CoV-2 SARS-CoV-2 variants T-cells Vaccination vaccines |
| title | COVID-19 vaccines: Immune correlates and clinical outcomes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T20%3A47%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19%20vaccines:%20Immune%20correlates%20and%20clinical%20outcomes&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Mahrokhian,%20Shant%20H.&rft.date=2024-12-31&rft.volume=20&rft.issue=1&rft.spage=2324549&rft.pages=2324549-&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2024.2324549&rft_dat=%3Cproquest_pubme%3E2974004172%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2974004172&rft_id=info:pmid/38517241&rft_doaj_id=oai_doaj_org_article_d5cddb4db5dc402cb1d85766789d8d24&rfr_iscdi=true |